Record Revenue and Net Product Sales
Total revenue of $69.5 million for Q3 2025, with record net product sales of $64.1 million, a 65% year-over-year increase. Raised 2025 revenue guidance to $285 million to $290 million, exceeding previous expectations.
Strong Performance of Commercial Products
TAVALISSE generated $44.7 million in net product sales, a 70% increase from Q3 2024. GAVRETO achieved $11.1 million, a 56% increase, and REZLIDHIA reported $8.3 million, a 50% increase.
Pipeline Advancements
Completion of enrollment in the dose escalation phase of the R289 study. First patient enrolled in the dose expansion phase. Strategic collaborations and expansions for olutasidenib in IDH1 mutated AML and glioma.
Financial Discipline and Profitability
Reported net income of $27.9 million for Q3 2025, up from $12.4 million in Q3 2024. Increased cash balance to $137.1 million.